Loading…
The African American Study of Kidney Disease: do these results indicate that 140/90 mm hg is good enough?
Current national guidelines recommend aggressive lowering of blood pressure (< 130/80 mm Hg) in patients with chronic kidney disease (CKD). In this paper, we summarize recent clinical trial data evaluating the effect of lower blood pressure goals on renal outcomes. The epidemiologic data relating...
Saved in:
Published in: | Current hypertension reports 2005-10, Vol.7 (5), p.363-366 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c326t-26f9c28d0ef82179b3eaded4f89e2cef309ae0a894310d1779d3da2adc59ae323 |
---|---|
cites | cdi_FETCH-LOGICAL-c326t-26f9c28d0ef82179b3eaded4f89e2cef309ae0a894310d1779d3da2adc59ae323 |
container_end_page | 366 |
container_issue | 5 |
container_start_page | 363 |
container_title | Current hypertension reports |
container_volume | 7 |
creator | Rahman, Mahboob El-Meanawy, Ashraf Romanello, Joseph |
description | Current national guidelines recommend aggressive lowering of blood pressure (< 130/80 mm Hg) in patients with chronic kidney disease (CKD). In this paper, we summarize recent clinical trial data evaluating the effect of lower blood pressure goals on renal outcomes. The epidemiologic data relating blood pressure to progression of kidney disease, the Modification of Diet in Renal Disease (MDRD) study (in patients with > 1 g proteinuria/d), and meta-analyses of angiotensin-converting enzyme (ACE) inhibitor clinical trials all support lower blood pressure goals in CKD patients, particularly those with proteinuria. The African American Study of Kidney Disease and Hypertension (AASK) supports lower blood pressure goals in terms of reduction of proteinuria, but demonstrates no additional benefit for clinical renal outcomes. Similarly, the second Ramipril Efficacy in Nephropathy study (REIN-2) shows that in patients with proteinuric nondiabetic renal disease who are receiving ACE inhibitors, a lower than usual blood pressure goal does not improve renal outcomes. However, there are limited clinical trial data evaluating the effects of low blood pressure on the increased cardiovascular risk seen in patients with CKD. Pending further clinical studies, current recommendations to target tight blood pressure control (< 130/80 mm Hg) in patients with CKD appear reasonable. |
doi_str_mv | 10.1007/s11906-005-0072-6 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68579410</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2409214651</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-26f9c28d0ef82179b3eaded4f89e2cef309ae0a894310d1779d3da2adc59ae323</originalsourceid><addsrcrecordid>eNpdkU1PwzAMhiMEgvHxA7igiAO3Mjtpm4YLmvgWkzgwzlHWuFvR2oymPezfk2mTkDhYtuzntSy_jF0i3CKAGgdEDXkCkMVQIskP2AgzmSYSEQ-3tYjNFNUJOw3hG0BETB2zE8wxU1DAiNWzJfFJ1dWlbfmkoV3x2Q9uw33F32vX0oY_1oFsoDvuPO-XFIh3FIZVH3jduqjoKbZtzzGFsQbeNHy54HXgC-8dp9YPi-X9OTuq7CrQxT6fsa_np9nDazL9eHl7mEyTUoq8T0Re6VIUDqgqBCo9l2QdubQqNImSKgnaEthCpxLBoVLaSWeFdWUWB1LIM3az27vu_M9AoTdNHUparWxLfggmLzKlU4QIXv8Dv_3QtfE2UyidAWZYRAh3UNn5EDqqzLqrG9ttDILZmmB2JphogtmaYPKoudovHuYNuT_F_uvyF9iRgHg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>879501518</pqid></control><display><type>article</type><title>The African American Study of Kidney Disease: do these results indicate that 140/90 mm hg is good enough?</title><source>Springer Nature</source><creator>Rahman, Mahboob ; El-Meanawy, Ashraf ; Romanello, Joseph</creator><creatorcontrib>Rahman, Mahboob ; El-Meanawy, Ashraf ; Romanello, Joseph</creatorcontrib><description>Current national guidelines recommend aggressive lowering of blood pressure (< 130/80 mm Hg) in patients with chronic kidney disease (CKD). In this paper, we summarize recent clinical trial data evaluating the effect of lower blood pressure goals on renal outcomes. The epidemiologic data relating blood pressure to progression of kidney disease, the Modification of Diet in Renal Disease (MDRD) study (in patients with > 1 g proteinuria/d), and meta-analyses of angiotensin-converting enzyme (ACE) inhibitor clinical trials all support lower blood pressure goals in CKD patients, particularly those with proteinuria. The African American Study of Kidney Disease and Hypertension (AASK) supports lower blood pressure goals in terms of reduction of proteinuria, but demonstrates no additional benefit for clinical renal outcomes. Similarly, the second Ramipril Efficacy in Nephropathy study (REIN-2) shows that in patients with proteinuric nondiabetic renal disease who are receiving ACE inhibitors, a lower than usual blood pressure goal does not improve renal outcomes. However, there are limited clinical trial data evaluating the effects of low blood pressure on the increased cardiovascular risk seen in patients with CKD. Pending further clinical studies, current recommendations to target tight blood pressure control (< 130/80 mm Hg) in patients with CKD appear reasonable.</description><identifier>ISSN: 1522-6417</identifier><identifier>EISSN: 1534-3111</identifier><identifier>DOI: 10.1007/s11906-005-0072-6</identifier><identifier>PMID: 16157080</identifier><language>eng</language><publisher>United States: Springer Nature B.V</publisher><subject>African Americans ; Antihypertensive Agents - therapeutic use ; Blood pressure ; Clinical trials ; Disease Progression ; Glomerular Filtration Rate ; Humans ; Hypertension ; Hypertension - complications ; Hypertension - drug therapy ; Kidney diseases ; Kidney Failure, Chronic - complications ; Kidney Failure, Chronic - prevention & control ; Medical treatment ; Meta-Analysis as Topic ; Proteinuria - complications ; Proteinuria - prevention & control ; Randomized Controlled Trials as Topic</subject><ispartof>Current hypertension reports, 2005-10, Vol.7 (5), p.363-366</ispartof><rights>Current Science Inc. 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c326t-26f9c28d0ef82179b3eaded4f89e2cef309ae0a894310d1779d3da2adc59ae323</citedby><cites>FETCH-LOGICAL-c326t-26f9c28d0ef82179b3eaded4f89e2cef309ae0a894310d1779d3da2adc59ae323</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16157080$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rahman, Mahboob</creatorcontrib><creatorcontrib>El-Meanawy, Ashraf</creatorcontrib><creatorcontrib>Romanello, Joseph</creatorcontrib><title>The African American Study of Kidney Disease: do these results indicate that 140/90 mm hg is good enough?</title><title>Current hypertension reports</title><addtitle>Curr Hypertens Rep</addtitle><description>Current national guidelines recommend aggressive lowering of blood pressure (< 130/80 mm Hg) in patients with chronic kidney disease (CKD). In this paper, we summarize recent clinical trial data evaluating the effect of lower blood pressure goals on renal outcomes. The epidemiologic data relating blood pressure to progression of kidney disease, the Modification of Diet in Renal Disease (MDRD) study (in patients with > 1 g proteinuria/d), and meta-analyses of angiotensin-converting enzyme (ACE) inhibitor clinical trials all support lower blood pressure goals in CKD patients, particularly those with proteinuria. The African American Study of Kidney Disease and Hypertension (AASK) supports lower blood pressure goals in terms of reduction of proteinuria, but demonstrates no additional benefit for clinical renal outcomes. Similarly, the second Ramipril Efficacy in Nephropathy study (REIN-2) shows that in patients with proteinuric nondiabetic renal disease who are receiving ACE inhibitors, a lower than usual blood pressure goal does not improve renal outcomes. However, there are limited clinical trial data evaluating the effects of low blood pressure on the increased cardiovascular risk seen in patients with CKD. Pending further clinical studies, current recommendations to target tight blood pressure control (< 130/80 mm Hg) in patients with CKD appear reasonable.</description><subject>African Americans</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Blood pressure</subject><subject>Clinical trials</subject><subject>Disease Progression</subject><subject>Glomerular Filtration Rate</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Hypertension - complications</subject><subject>Hypertension - drug therapy</subject><subject>Kidney diseases</subject><subject>Kidney Failure, Chronic - complications</subject><subject>Kidney Failure, Chronic - prevention & control</subject><subject>Medical treatment</subject><subject>Meta-Analysis as Topic</subject><subject>Proteinuria - complications</subject><subject>Proteinuria - prevention & control</subject><subject>Randomized Controlled Trials as Topic</subject><issn>1522-6417</issn><issn>1534-3111</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNpdkU1PwzAMhiMEgvHxA7igiAO3Mjtpm4YLmvgWkzgwzlHWuFvR2oymPezfk2mTkDhYtuzntSy_jF0i3CKAGgdEDXkCkMVQIskP2AgzmSYSEQ-3tYjNFNUJOw3hG0BETB2zE8wxU1DAiNWzJfFJ1dWlbfmkoV3x2Q9uw33F32vX0oY_1oFsoDvuPO-XFIh3FIZVH3jduqjoKbZtzzGFsQbeNHy54HXgC-8dp9YPi-X9OTuq7CrQxT6fsa_np9nDazL9eHl7mEyTUoq8T0Re6VIUDqgqBCo9l2QdubQqNImSKgnaEthCpxLBoVLaSWeFdWUWB1LIM3az27vu_M9AoTdNHUparWxLfggmLzKlU4QIXv8Dv_3QtfE2UyidAWZYRAh3UNn5EDqqzLqrG9ttDILZmmB2JphogtmaYPKoudovHuYNuT_F_uvyF9iRgHg</recordid><startdate>20051001</startdate><enddate>20051001</enddate><creator>Rahman, Mahboob</creator><creator>El-Meanawy, Ashraf</creator><creator>Romanello, Joseph</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20051001</creationdate><title>The African American Study of Kidney Disease: do these results indicate that 140/90 mm hg is good enough?</title><author>Rahman, Mahboob ; El-Meanawy, Ashraf ; Romanello, Joseph</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-26f9c28d0ef82179b3eaded4f89e2cef309ae0a894310d1779d3da2adc59ae323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>African Americans</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Blood pressure</topic><topic>Clinical trials</topic><topic>Disease Progression</topic><topic>Glomerular Filtration Rate</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Hypertension - complications</topic><topic>Hypertension - drug therapy</topic><topic>Kidney diseases</topic><topic>Kidney Failure, Chronic - complications</topic><topic>Kidney Failure, Chronic - prevention & control</topic><topic>Medical treatment</topic><topic>Meta-Analysis as Topic</topic><topic>Proteinuria - complications</topic><topic>Proteinuria - prevention & control</topic><topic>Randomized Controlled Trials as Topic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rahman, Mahboob</creatorcontrib><creatorcontrib>El-Meanawy, Ashraf</creatorcontrib><creatorcontrib>Romanello, Joseph</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Current hypertension reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rahman, Mahboob</au><au>El-Meanawy, Ashraf</au><au>Romanello, Joseph</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The African American Study of Kidney Disease: do these results indicate that 140/90 mm hg is good enough?</atitle><jtitle>Current hypertension reports</jtitle><addtitle>Curr Hypertens Rep</addtitle><date>2005-10-01</date><risdate>2005</risdate><volume>7</volume><issue>5</issue><spage>363</spage><epage>366</epage><pages>363-366</pages><issn>1522-6417</issn><eissn>1534-3111</eissn><abstract>Current national guidelines recommend aggressive lowering of blood pressure (< 130/80 mm Hg) in patients with chronic kidney disease (CKD). In this paper, we summarize recent clinical trial data evaluating the effect of lower blood pressure goals on renal outcomes. The epidemiologic data relating blood pressure to progression of kidney disease, the Modification of Diet in Renal Disease (MDRD) study (in patients with > 1 g proteinuria/d), and meta-analyses of angiotensin-converting enzyme (ACE) inhibitor clinical trials all support lower blood pressure goals in CKD patients, particularly those with proteinuria. The African American Study of Kidney Disease and Hypertension (AASK) supports lower blood pressure goals in terms of reduction of proteinuria, but demonstrates no additional benefit for clinical renal outcomes. Similarly, the second Ramipril Efficacy in Nephropathy study (REIN-2) shows that in patients with proteinuric nondiabetic renal disease who are receiving ACE inhibitors, a lower than usual blood pressure goal does not improve renal outcomes. However, there are limited clinical trial data evaluating the effects of low blood pressure on the increased cardiovascular risk seen in patients with CKD. Pending further clinical studies, current recommendations to target tight blood pressure control (< 130/80 mm Hg) in patients with CKD appear reasonable.</abstract><cop>United States</cop><pub>Springer Nature B.V</pub><pmid>16157080</pmid><doi>10.1007/s11906-005-0072-6</doi><tpages>4</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1522-6417 |
ispartof | Current hypertension reports, 2005-10, Vol.7 (5), p.363-366 |
issn | 1522-6417 1534-3111 |
language | eng |
recordid | cdi_proquest_miscellaneous_68579410 |
source | Springer Nature |
subjects | African Americans Antihypertensive Agents - therapeutic use Blood pressure Clinical trials Disease Progression Glomerular Filtration Rate Humans Hypertension Hypertension - complications Hypertension - drug therapy Kidney diseases Kidney Failure, Chronic - complications Kidney Failure, Chronic - prevention & control Medical treatment Meta-Analysis as Topic Proteinuria - complications Proteinuria - prevention & control Randomized Controlled Trials as Topic |
title | The African American Study of Kidney Disease: do these results indicate that 140/90 mm hg is good enough? |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T01%3A03%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20African%20American%20Study%20of%20Kidney%20Disease:%20do%20these%20results%20indicate%20that%20140/90%20mm%20hg%20is%20good%20enough?&rft.jtitle=Current%20hypertension%20reports&rft.au=Rahman,%20Mahboob&rft.date=2005-10-01&rft.volume=7&rft.issue=5&rft.spage=363&rft.epage=366&rft.pages=363-366&rft.issn=1522-6417&rft.eissn=1534-3111&rft_id=info:doi/10.1007/s11906-005-0072-6&rft_dat=%3Cproquest_cross%3E2409214651%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c326t-26f9c28d0ef82179b3eaded4f89e2cef309ae0a894310d1779d3da2adc59ae323%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=879501518&rft_id=info:pmid/16157080&rfr_iscdi=true |